Biocon Biologics recognized as Asia IP Elite for 2025 by IAM

Bengaluru: Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon has announced that it has been recognized as an Asia IP Elite for 2025 by IAM (Intellectual Asset Management), the world’s leading Intellectual Property (IP) publication.

This prestigious accolade is awarded to a select group of Asia-based organizations that have demonstrated exceptional IP value creation and are considered leaders in the region. The award was presented during IPBC Asia, held in Tokyo from November 18–20, 2025.

Biocon first earned its place on the Asia IP Elite list in 2016. In subsequent years, Biocon Biologics has continued this legacy, with the two entities together being among the few Indian pharmaceutical companies consistently featured on the Asia IP Elite roster. The 2025 recognition marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, “Our inclusion in the Asia IP Elite list for 2025 marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list. This reflects our sustained commitment to innovation and strong intellectual property strategy. It reinforces our growing stature as a global biosimilars leader and the role of our IP strategy in expanding access to high-quality, affordable therapies for patients worldwide.”

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite.

Read also: Biocon Chief Kiran Mazumdar-Shaw wins USC Business Management Award